VF
SBBP

Virtu Financial’s Strongbridge Biopharma plc. SBBP Stock Holding History

Virtu Financial’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-13,991
Closed -$29K – 1950
2020
Q3 		$29K Buy
13,991
+1,189
+9% +$4.01K 0.01% 891
2020
Q2 		$48K Buy
+12,802
New +$38.4K 0.01% 1008

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Virtu Financial's SBBP Position: Q4 2020 in Review

Virtu Financial sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2020, closing a stake of 13,991 shares — an estimated $29K sold.

Virtu Financial first reported a position in SBBP in Q2 2020 and held it in 2 quarters. The position peaked at $48K in Q2 2020. 71 funds tracked by Wall St. Rank hold SBBP as of Q4 2020.

  • Virtu Financial reported no remaining Strongbridge Biopharma plc. position as of Q4 2020 after selling out during the quarter.
  • Virtu Financial sold 13,991 Strongbridge Biopharma plc. shares in Q4 2020, an estimated $29K.
  • Virtu Financial first reported a position in Strongbridge Biopharma plc. in Q2 2020 and held it in 2 quarters.
  • Virtu Financial's Strongbridge Biopharma plc. position peaked at $48K in Q2 2020.
  • 71 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2020.

Based on Virtu Financial's 13F filing for Q4 2020, filed 24 Feb 2021.